Enhanced mRNA Therapeutic Delivery with Redox-Responsive Smart Nanocarriers
Background
Messenger RNA (mRNA)-based therapeutics have expanded beyond their success in COVID-19 vaccines to include cancer immunotherapy, gene editing, and protein replacement therapy for rare diseases. To ensure that injected mRNA remains intact and reaches target cells, a delivery system is essential for safe and effective transport. Lipid nanoparticles (LNPs), widely used in clinical settings, have demonstrated their utility but still require improvement. Key limitations include lower-than-expected intracellular delivery efficiency and potential immunogenicity due to accumulation in the body after repeated administration.
Conventional LNPs tend to be trapped in endosomes after crossing the cell membrane, leading to mRNA degradation if they cannot escape. To efficiently release therapeutic genetic material into the cytoplasm, the development of intelligent materials that change their structure in response to specific microenvironments is crucial. This has led researchers to focus on developing smart nanocarriers that can precisely release drugs by recognizing physiological characteristics of disease sites or cells.
Key Findings
The researchers comprehensively analyzed various nanocarrier technologies that utilize redox (oxidation-reduction) responsiveness, considering the chemical environment both inside and outside cells. Compared to normal cells, the intracellular and tumor microenvironments exhibit significantly higher glutathione (GSH) concentrations (hundreds of times higher) and increased production of reactive oxygen species (ROS). Nanomaterials designed to release drugs in response to these concentration differences are the core of redox-responsive nanocarriers.
The main technology platforms are classified into reduction-responsive, oxidation-responsive, and dual-responsive systems. Reduction-responsive carriers incorporate disulfide bonds into their molecular structure, allowing them to break down and rapidly release mRNA when exposed to high GSH concentrations within cells. Oxidation-responsive platforms utilize the characteristic of certain hydrophobic materials changing to hydrophilic in the excessive ROS environment of tumors or inflammatory sites, inducing the breakdown of the carrier. Recently, hybrid nanocarriers combining the advantages of polymers and lipids have been synthesized, successfully enhancing both stability and cell permeability. These carriers are precisely controlled to maintain their integrity during circulation in the body and disassemble upon entering cells.
Significance and Outlook
Redox-responsive smart nanocarriers have the potential to significantly improve the targeted delivery efficiency of mRNA therapeutics. By greatly improving the efficiency of endosomal escape, which is the process by which therapeutic molecules reach the cytoplasm, they can enhance therapeutic effects and reduce the required dosage. This, in turn, can mitigate systemic side effects associated with drug overdoses.
However, there are clear challenges to be addressed before commercialization. The long-term safety of nanomaterials in terms of their degradation and excretion in the body must be definitively demonstrated. The technology also needs further research to control potential immunogenicity that may arise during repeated administration. Furthermore, the standardization of manufacturing processes for the large-scale production of uniform-quality nanoparticles is a critical industrial hurdle. In the future, researchers plan to introduce artificial intelligence (AI) to predict optimal responsive chemical structures and expand the scope of application to personalized theranostic systems that combine diagnosis and treatment.
Messenger RNA (mRNA) therapeutics have emerged as a transformative biomedical platform with broad potential in vaccination, protein replacement, gene editing, and cancer immunotherapy. Despite substantial progress, the broader clinical translation of mRNA therapeutics requires further optimization of delivery systems to address challenges related to stability, biodistribution, intracellular delivery efficiency, and biosafety. In this review, we discuss the rational design of redox-responsive nanomaterials that exploit physiological intracellular redox compartmentalization or, in selected systems, disease-associated oxidative or reductive dysregulation to improve mRNA delivery. We first summarize the biological basis of redox-responsive delivery by linking disease-associated redox imbalance with the engineering principles of responsive nanomaterials. We then systematically discuss major classes of redox-responsive systems, including oxidation-responsive, reduction-responsive, and dual-responsive platforms across polymeric, lipid-based, and hybrid nanomaterial formulations. Particular emphasis is placed on how distinct chemical architectures and responsive motifs influence intracellular delivery behavior, cargo release, immune compatibility, and therapeutic performance. Finally, we discuss current translational challenges, including long-term biosafety, repeated administration, immunogenicity, and large-scale manufacturing, while highlighting emerging opportunities such as AI-assisted material design and personalized theranostic applications. Collectively, this review provides a comprehensive framework for understanding how redox-responsive nanomaterial engineering may advance the next generation of precise and clinically translatable mRNA therapeutics.
This technology is expected to accelerate the commercialization of personalized immunotherapies and gene editing technologies for patients with difficult-to-treat cancers. By designing drugs to be released only in the unique redox environment of tumor tissues, it minimizes toxicity to normal cells. For example, nanoparticles loaded with patient-specific cancer vaccines can be injected intravenously and designed to induce the production of target proteins only within immune cells in the liver and other lymphoid organs. In genetic metabolic diseases requiring repeated administration, it can also improve safety and open up the possibility of long-term treatment. If an AI-based platform is established to rapidly screen for optimal lipid structures during the manufacturing process, the drug development period can also be significantly shortened.